The Ides of March – FDA’s Pharmaceutical and Clinical Pharmacology Advisory Committee Meeting

Ellen Leinfuss

While ominously scheduled for March 15, no such drama (like the assassination of Julius Caesar, the origins of ‘beware the Ides of March’) occurred during the FDA’s Pharmaceutical Science and Clinical Pharmacology Advisory Committee meeting. It was quite productive, acknowledging the tremendous impact of modeling and simulation in drug development and regulatory review moving the technology further into the mainstream.

Read More
Topics: Model-based Drug Development, PBPK Modeling and Simulation
Learn More
LinkedIn